Novo Nordisk’s oral semaglutide Rybelsus reduced the risk for major adverse cardiovascular events by 14% in people with type ...
The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback